Table 2.
Prevalence and anatomic site of gonorrhea (GC) and chlamydia (CT) infections at baseline and follow-up visits
| Anatomic site of infection | Control arm | EPT arm | ||
|---|---|---|---|---|
| Baseline (N = 84)a |
Follow-up (N = 72) |
Baseline (N = 89) |
Follow-up (N = 83) |
|
| Any site/any pathogen |
n = 79b
94.0% (86.8–97.4%) |
n = 2c
2.8% (0.8–9.6%) |
n = 81 91.0% (83.2–95.4%) |
n = 2 2.4% (0.7–8.4%) |
| Urethral CT |
n = 4 5.1% (2.0–12.3%) |
n = 10 11.2% (6.2–19.5%) |
||
| Urethral GC |
n = 6 7.1% (3.3–14.7%) |
n = 11 12.4% (7.0–20.8%) |
||
| Urethral CT and GC |
n = 2 2.4% (0.6–8.3%) |
n = 5 6.2% (2.7–13.6%) |
||
| Rectal CT |
n = 24 28.6% (20.0–39.0%) |
n = 2 2.8% (0.8–9.6%) |
n = 32 36.0% (26.8–46.3%) |
n = 1 1.2% (0.2–6.5%) |
| Rectal GC |
n = 12 14.3% (8.4–23.3%) |
n = 4 4.5% (1.8–11.0%) |
||
| Rectal CT and GC |
n = 9 10.7% (5.7–19.1%) |
n = 5 6.2% (2.7–13.6%) |
||
| Pharyngeal CT |
n = 8 9.5% (4.9–17.7%) |
n = 1 7.9% (3.9–15.4%) |
||
| Pharyngeal GC |
n = 15 17.9% (11.1–27.4%) |
n = 21 25.9% (17.6–36.4%) |
n = 1 1.2% (0.2–6.5%) |
|
| Pharyngeal CT and GC |
n = 1 1.2% (0.2–7.4%) |
n = 1 1.2% (0.2–6.7%) |
||
aSubtotals do not add to 100% as individual participants may have had multiple pathogens and/or anatomic sites of infection
bFive subjects enrolled in the control arm and eight participants in the EPT arm diagnosed with symptomatic disease subsequently tested negative for GC/CT infection by TMA
cOnly cases of infection with the same organism in the same anatomic site at follow-up reported